Lilly completes acquisition of ImClone Systems

Published: 25-Nov-2008

Eli Lilly & Co has completed its $6 bn acquisition of ImClone Systems Inc. The biotech business is now a wholly-owned subsidiary of Lilly.


Eli Lilly & Co has completed its $6 bn acquisition of ImClone Systems Inc. The biotech business is now a wholly-owned subsidiary of Lilly.

ImClone entered into a deal back in on October, 2008, after Lilly outbid two prior offers from Bristol-Myers Squibb, ImClone's partner on the cancer drug Erbitux.

Lilly president and ceo John Lechleiter said: "We are excited about the successful completion of the ImClone transaction, which will broaden Lilly's portfolio of marketed cancer therapies and boost Lilly's oncology pipeline with up to three promising targeted therapies in Phase III in 2009,"

He said the acquisition adds late-stage assets, early- and mid-stage prospects, and the opportunity to generate additional value from Erbitux, a blockbuster targeted cancer therapy. ImClone's ceo, John Johnson, retains his current position at ImClone will report directly to Lechleiter.

You may also like